NKTX Nkarta, Inc.
Nkarta, Inc. (NKTX) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.40 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.4% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Nkarta, Inc.
Nkarta Inc. is a biopharmaceutical company. It develops and commercializes cell therapies for cancer treatment. The company's product candidate includes NKX101 and NKX019, which are in clinical stage. Nkarta Inc. is based in South San Francisco, California.
Sector
Healthcare
Industry
Biotechnology